Vanda Pharmaceuticals Inc. · NASDAQ:VNDA

Vanda Pharmaceuticals — Investor Presentation (January 2024)

45 slides from Vanda Pharmaceuticals's investor presentation, January 2024

  1. Slide 1: 2024 Corporate Presentation

    2024 CORPORATE PRESENTATION January 2024

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Various statements in this presentation, including, but not limited to statements regarding Vanda’s commercial products, plans and opportunities, as well as statements about Vanda’s products in development and the related clinical development and regulatory timelines and c

  3. Slide 3: Vanda Pharmaceuticals Inc. (VNDA)

    Vanda Pharmaceuticals Inc. (VNDA) Vanda is a leading global biopharmaceutical company dedicated to innovating in the service of people’s pursuit of happiness Commercialized Robust pipeline Strong Financial Products Recent regulatory Position HETLIOZ® submissions HETLIOZ LQ® Approx. $490 million Mult

  4. Slide 4: Recent acquisition of PONVORY from Johnson & Johnson Company

    Recent acquisition of PONVORY® from Johnson & Johnson Company In December 2023, Vanda acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd., a Johnson & Johnson Company, for $100 million. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and H

  5. Slide 5: Commercialized Products

    Commercialized Products 02 • HETLIOZ® oral capsules are approved in the U.S. • Fanapt® is approved in the U.S. for the treatment • PONVORY® is indicated for the treatment of and Europe for the treatment of Non-24-Hour of adults with schizophrenia. relapsing forms of multiple sclerosis (MS), to Sleep

  6. Slide 6: Clinical Development Pipeline: Key Milestones

    Clinical Development Pipeline: Key Milestones Vanda pursuing FDA approval for the following: Product Indication Fanapt® Bipolar (PDUFA Date: 4/2/2024) HETLIOZ® Insomnia (PDUFA Date: 3/4/2024) Tradipitant Gastroparesis (PDUFA Date: 9/18/2024) Other recent and upcoming clinical and regulatory developm

  7. Slide 7: Strategic Focus

    Strategic Focus Increase Advance Consumer revenue pipeline focus Organically through Late / early-stage Increase access and existing products programs affordability for patients Business development Emerging ASO Engage directly with opportunities platform consumer 7

  8. Slide 8: Commercial Priorities & Milestones

    Commercial Priorities & Milestones Tradipitant • Continued focus on market for • Retain market share despite • Re-launch in existing • Pursue FDA approval for schizophrenia generic competition through multiple sclerosis (MS) tradipitant in patients with • Pursue FDA approval for focus on patient loy

  9. Slide 9: Fanapt for Schizophrenia

    Fanapt® for Schizophrenia: • About 1% of adult population • Patients frequently switch worldwide is diagnosed with antipsychotic treatments due to schizophrenia1 side effects2 • About 3 million people in the U.S. • Side effects include metabolic, live with schizophrenia weight and movement disorders

  10. Slide 10: HETLIOZ for Non-24-Hour Sleep-Wake Disorder (Non-24)

    HETLIOZ® for Non-24-Hour Sleep-Wake Disorder (Non-24) Key demographics Blind individuals Sighted individuals Misaligned circadian with Non-24 with Non-24 timing system ~70% totally blind have Non-241 Non-24 is comorbid with depressive and bipolar disorders3 Prevalence of Non-24 in the general popula

  11. Slide 11: HETLIOZ for Smith-Magenis Syndrome (SMS)

    HETLIOZ® for Smith-Magenis Syndrome (SMS) • HETLIOZ® first approved treatment for nighttime sleep disturbances in SMS (December 2020) • Pursuing approval in the E.U. market • Severe sleep disorder is the strongest predictor of maladaptive behavior 15,000 Chromosomal deletion of 17p11.2 Major physica

  12. Slide 12: HETLIOZ for Smith-Magenis Syndrome (SMS)

    HETLIOZ® for Smith-Magenis Syndrome (SMS) 1. December 2020: FDA approves HETLIOZ® & HETLIOZ LQ® for the treatment of nighttime sleep disturbances in patients with SMS 2. Patients from the ongoing open label clinical study have been contacted and are at different stages of working with their doctors

  13. Slide 13: Research and Development

    Research and Development 13

  14. Slide 14: Late-Stage Clinical Development Pipeline

    Late-Stage Clinical Development Pipeline Product Indication Preclinical Phase I Phase II Phase III Regulatory Jet Lag Disorder Insomnia Delayed Sleep Phase Disorder (DSPD) Non-24 Pediatric Bipolar I Disorder Long Acting Injectable (LAI) TBD TBD Gastroparesis Tradipitant Motion Sickness Atopic Dermat

  15. Slide 15: HETLIOZ Lifecycle Management

    HETLIOZ® Lifecycle Management 15

  16. Slide 16: HETLIOZ Lifecycle Management Programs

    HETLIOZ® Lifecycle Management Programs 1 Jet Lag Disorder • Clinical program completed 2 Insomnia • Clinical program completed; sNDA accepted for filing with PDUFA target action date of 3/4/2024 3 Delayed Sleep Phase Disorder • Phase III program initiated 4 Non-24 Pediatric • Phase III clinical prog

  17. Slide 17: Fanapt Lifecycle Management

    Fanapt® Lifecycle Management 17

  18. Slide 18: Fanapt Lifecycle Management Programs

    Fanapt® Lifecycle Management Programs 1 Bipolar I Disorder • Phase III program complete; positive results announced in December 2022 • Pursuing FDA approval for Fanapt® in the indication of bipolar I disorder in adults; sNDA accepted for filing with PDUFA target action date of 4/2/2024 2 Long Acting

  19. Slide 19: Bipolar I Disorder

    Bipolar I Disorder 19

  20. Slide 20: Fanapt for Bipolar I Disorder

    Fanapt® for Bipolar I Disorder Results reported in December 2022 ~ 1 million adults • Thein theIII study Phase U.S.enrolled withapproximately 400 volunteers with a history of bipolar I disorder suffering Parkinson’s Disease from a current episode of mania.1 • The primary endpoint was assessed by the

  21. Slide 21: Fanapt for Bipolar I Disorder

    Fanapt® for Bipolar I Disorder Results reported in December 2022 ~ 1 million adults in the U.S. with • The secondary endpoints, Clinician Global Impression of Severity (CGI-S) and Clinician Parkinson’s Disease Global Impression 1 of Change (CGI-C), also achieved statistical significance (p=0.0005 an

  22. Slide 22: Tradipitant Programs

    Tradipitant Programs 22

  23. Slide 23: Tradipitant Programs

    Tradipitant Programs 1 Gastroparesis • Phase III study results reported in February 2022; 12-week study of ~200 patients with idiopathic or diabetic gastroparesis • Phase II positive study with results reported in December 2018 and published in Gastroenterology in January 2021 • Pursuing FDA approva

  24. Slide 24: Gastroparesis

    Gastroparesis 24

  25. Slide 25: Tradipitant for Gastroparesis

    Tradipitant for Gastroparesis • Completed two clinical studies of tradipitant in gastroparesis. NDA accepted for filing with PDUFA target action date of 9/18/2024. • Gastroparesis is a significant unmet medical need. • Last treatment approved more than 40 years ago1. 600,000 300,000 6 million diagno

  26. Slide 26: Gastroparesis – Symptoms & Clinical Expression

    Gastroparesis – Symptoms & Clinical Expression1 Diabetic or Idiopathic Gastroparesis Chronic Nausea Vomiting Patients with gastroparesis suffer from chronic, severe and Gastroparesis can cause debilitating nausea. vomiting, which can lead to weight loss and hospitalization due to nutritional deficie

  27. Slide 27: Tradipitant Gastroparesis Clinical Program

    Tradipitant Gastroparesis Clinical Program 1 Phase II Study (VP-VLY-686-2301) • 4-week study of approximately 150 adult patients with diabetic or idiopathic gastroparesis • Tradipitant was shown to be effective in improving nausea and overall symptoms in patients with gastroparesis • Efficacy establ

  28. Slide 28: Gastroparesis – Phase II Study

    Gastroparesis – Phase II Study Results reported in December 2018, published in Gastroenterology January 20211 Study Design Population Assessments o 4 weeks of double-blind treatment o Approximately 150 randomized o Patient Reported Daily Diary: followed by optional 8 weeks of subjects Nausea, Vomiti

  29. Slide 29: Gastroparesis – Phase III Study

    Gastroparesis – Phase III Study Study is complete and results were reported in February 2022 Study Design Population Assessments o 12 weeks of double-blind o Approximately 200 randomized o Patient Reported Daily Diary: treatment subjects Nausea, Vomiting & Other o 85 mg b.i.d. o Stratified by idiopa

  30. Slide 30: Gastroparesis – Pooled Study Results

    Gastroparesis – Pooled Study Results • Vanda completed a pooled analysis of two clinical studies of tradipitant in gastroparesis. • Population of 342 patients with relevant clinical endpoints. • Both studies were large multi-site, randomized, double-blind, placebo-controlled studies • Tradipitant wa

  31. Slide 31: Gastroparesis – Pooled Study Results

    Gastroparesis – Pooled Study Results Figure 1 and Table 1 show the results of such pooled analysis of all patients randomized in the two studies (intent to treat population, ITT) and Figure 2 and Table 2 show the results for the same parameters in the population of patients who were judged as compli

  32. Slide 32: Motion Sickness

    Motion Sickness 32

  33. Slide 33: Tradipitant for Motion Sickness

    Tradipitant for Motion Sickness Neurokinin-1 (NK-1) receptor antagonists have the potential to be effective in improving the symptoms of motion sickness, given the involvement of substance P in nauseogenic and emetic pathways and the expression of NK-1 receptors in the gastrointestinal system.1 The

  34. Slide 34: Motion Sickness – Phase II Study Results

    Motion Sickness – Phase II Study Results Results reported in July 2019, published in Frontiers in Neurology in September 20201 • Tradipitant was shown to be effective in preventing motion sickness1 • An exploratory analysis was performed to evaluate the effects of tradipitant under “calm” and “rough

  35. Slide 35: Motion Sickness – Phase II Study Results

    Motion Sickness – Phase II Study Results Results reported in July 2019, published in Frontiers in Neurology in September 20201 • Tradipitant was shown to be effective in preventing motion sickness1 • An exploratory analysis was performed to evaluate the effects of tradipitant under “calm” and “rough

  36. Slide 36: Motion Sickness: Phase III Program

    Motion Sickness: Phase III Program • Phase III study completed – Positive results in prevention of vomiting • Second Phase III study initiated • Open label safety study started Enrollment Program Timeline o First Phase III Study: o First Phase III results reported in o Randomized: 365 May 2023 o 85

  37. Slide 37: Motion Sickness: Phase III Study

    Motion Sickness: Phase III Study • 365 participant study across 34 boat trips in coastal waters of U.S. from November 2021 to April 2023 • Participants randomized 1:1:1 tradipitant 170mg v tradipitant 85mg v placebo 1 hour prior to departure • Approximately 4-hour trips with questionnaires of vomiti

  38. Slide 38: Early-Stage Programs

    Early-Stage Programs 38

  39. Slide 39: Early-Stage Programs

    Early-Stage Programs Cystic Fibrosis Transmembrane Conductance Regulators (CFTR) • VSJ-110 – CFTR Activator: VSJ-110 has shown efficacy in a dry eye model¹ and exhibited anti- inflammatory properties in both in vitro and in vivo assays • Ongoing Phase II Conjunctivitis Study investigating anti-infla

  40. Slide 40: Early-Stage Programs

    Early-Stage Programs Antisense Oligonucleotide (ASO) • VCA-894A was granted Orphan Drug Designation for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic splice site variants within IGHMBP2. • In September 2022, Vanda and OliPass Corporation (OliPass) announced

  41. Slide 41: Financial Results

    Financial Results 41

  42. Slide 42: Q3 2023 Financial Highlights

    2023 Financial Highlights Q3 2023 Financial Highlights $38.8 million Total net product sales from HETLIOZ® and Fanapt® were $38.8 million in the third quarter of 2023 HETLIOZ® net product sales were Fanapt® net product sales were $17.5 million in the third quarter of $21.3 million in the third quart

  43. Slide 43: Financials – Results Through September 30, 2023

    Financials – Results Through September 30, 2023 Results Through September 30, 2023 HETLIOZ® Net Product Sales $79.1M Fanapt® Net Product Sales $68.3M Total Revenues $147.4M Cost of Goods Sold $11.3M Research & Development $52.5M Selling, General & Administrative $89.3M Intangible Asset Amortization

  44. Slide 44: For more information on HETLIOZ and Fanapt

    For more information on HETLIOZ®, please visit www.HETLIOZ.com For more information on Fanapt®, please visit www.FANAPT.com 44

  45. Slide 45: Slide 45

Vanda Pharmaceuticals — Investor Presentation (January 2024) on 6ix